PharmaCom BioVet, Inc. (PHMB)
EXPM EXPM Primary Summary
PharmaCom BioVet, Inc. (PHMB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has PharmaCom BioVet, Inc. ever had a stock split?
PharmaCom BioVet, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ira Frohman CEO | EXPM Exchange | US71720A1079 ISIN |
| US Country | - Employees | - Last Dividend | 10 Sep 2008 Last Split | - IPO Date |
Overview
PharmaCom BioVet, Inc. is a leading force in the veterinary healthcare sector, with a specific focus on providing advanced cancer treatment solutions for companion animals across the United States. Established in 1995 and originally operating as ABV Gold Inc., the company underwent a strategic rebranding to PharmaCom BioVet, Inc. in August 2008. With its headquarters in Raleigh, North Carolina, PharmaCom BioVet, Inc. is at the forefront of veterinary oncology, dedicating its efforts to the research, development, and application of innovative treatments including bone marrow transplantation. This dedication not only showcases their commitment to veterinary healthcare but also highlights their role in revolutionizing the approach towards managing incurable diseases and conditions in companion animals, particularly those diagnosed with lymphoma and various other types of cancers.
Products and Services
PharmaCom BioVet, Inc. offers a range of proprietary devices and compounds, each designed to significantly improve the quality of life for companion animals facing cancer and other incurable diseases. Below is a detailed overview of their key offerings:
- Bone Marrow Transplantation: An advanced treatment procedure aimed at companion animals diagnosed with lymphoma and other cancers. This service utilizes state-of-the-art technology to replace diseased bone marrow with healthy cells, potentially offering a new lease on life for affected animals.
- Proprietary Devices: The company holds licenses for a series of innovative devices specifically engineered to aid in the diagnosis, treatment, and management of cancer in companion animals. These devices are part of PharmaCom BioVet, Inc.’s commitment to reducing suffering and improving treatment outcomes for pets with cancer.
- Proprietary Compounds: Alongside their devices, PharmaCom BioVet, Inc. has developed a range of compounds designed to combat cancer more effectively in companion animals. These compounds work in various ways to inhibit cancer growth, reduce symptoms, and improve the overall well-being of pets undergoing treatment.
Contact Information
